

# General practice study of Nicotine Replacement Therapy (NRT) assisted smoking cessation

<b>Submission date</b> 12/10/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 16/11/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/12/2011	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Michael Murphy

**Contact details**  
Smoking Research Group  
Department of clinical Pharmacology  
University of Oxford  
Radcliffe Infirmary  
Woodstock Road  
Oxford  
United Kingdom  
OX2 6HE

## Additional identifiers

**Protocol serial number**  
N0032117035

## Study information

**Scientific Title**

**Acronym**

Patch In Practice (PIP)

**Study objectives**

1. Assess whether extremes of behavioural support make a difference to quit rates
2. Study whether an individual's response to NRT is influenced by genetic constitution
3. Describe the relationship between nicotine load whilst smoking and that derived from transdermal patch

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Smoking cessation

**Interventions**

PIP is an open randomised controlled trial of two levels of behavioural support. One of the aims of the study is to assess response of moderately addicted smokers making a Nicotine Replacement Therapy (NRT) assisted quit attempt when randomised to low or moderate behavioural support within general practice.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Nicotine

**Primary outcome(s)**

Continuous abstinence by self-report and carbon dioxide at 1 week, 4 weeks, and 12 weeks in relation to genotype and 4 weeks for replacement.

**Key secondary outcome(s)**

1. Continuous abstinence at 1, 3, 6 and 12 months
2. Point prevalence abstinence at 1 week, 4 weeks, 3, 6 and 12 months by self report

**Completion date**

31/03/2006

## Eligibility

**Key inclusion criteria**

1. Greater than 18 years of age
2. Smoke 10 or more cigarettes per day
3. Wish to try to give up completely

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Pregnant or breast feeding
2. Using NRT or Zyban

**Date of first enrolment**

01/08/2002

**Date of final enrolment**

31/03/2006

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Smoking Research Group**

Oxford

United Kingdom

OX2 6HE

# Sponsor information

## Organisation

University of Oxford (UK)

## ROR

<https://ror.org/052gg0110>

# Funder(s)

## Funder type

Charity

## Funder Name

Cancer Research UK (CRUK) (UK)

## Alternative Name(s)

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	01/10/2007		Yes	No